Using a targeted antibody to treat advanced prostate cancer
Targeting MUC1-C with an antibody drug conjugate for the therapy of advanced prostate cancer
['FUNDING_R21'] · DANA-FARBER CANCER INST · NIH-10512804
This study is testing a new treatment for advanced prostate cancer that doesn't respond to current therapies, using a special antibody to deliver a drug directly to the cancer cells, and patients may have the chance to participate in trials to see how well it works and if it's safe.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DANA-FARBER CANCER INST (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10512804 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new treatment for patients with advanced prostate cancer, particularly those with forms that are resistant to current therapies. It involves creating a specialized antibody that targets a protein called MUC1-C, which is overexpressed in aggressive prostate cancer types. The antibody is designed to deliver a drug directly to cancer cells, potentially improving treatment effectiveness. Patients may be involved in clinical trials to test this new therapy's safety and efficacy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with refractory castrate resistant prostate cancer or neuroendocrine prostate cancer.
Not a fit: Patients with early-stage prostate cancer or those whose cancer is not resistant to current therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients with advanced prostate cancer who currently have limited options.
How similar studies have performed: Other research has shown promise in targeting similar proteins with antibody-drug conjugates, indicating potential for success in this approach.
Where this research is happening
BOSTON, UNITED STATES
- DANA-FARBER CANCER INST — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KUFE, DONALD W. — DANA-FARBER CANCER INST
- Study coordinator: KUFE, DONALD W.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.